Lifeward (LFWD) Competitors

89.7% of Health Sciences Acquisitions Co. 2 shares are held by institutional investors. Comparatively, 26.8% of Lifeward shares are held by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are held by insiders. Comparatively, 1.5% of Lifeward shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Lifeward.

Health Sciences Acquisitions Co. 2 has a net margin of 0.00% compared to Lifeward's net margin of -141.28%. Health Sciences Acquisitions Co. 2's return on equity of 0.00% beat Lifeward's return on equity.

In the previous week, Lifeward had 2 more articles in the media than Health Sciences Acquisitions Co. 2. MarketBeat recorded 2 mentions for Lifeward and 0 mentions for Health Sciences Acquisitions Co. 2. Health Sciences Acquisitions Co. 2's average media sentiment score of 0.00 equaled Lifeward'saverage media sentiment score.

Lifeward has a consensus price target of $10.00, suggesting a potential upside of 49.93%. Given Lifeward's stronger consensus rating and higher probable upside, analysts plainly believe Lifeward is more favorable than Health Sciences Acquisitions Co. 2.

Health Sciences Acquisitions Co. 2 has a beta of 0.09, suggesting that its share price is 91% less volatile than the broader market. Comparatively, Lifeward has a beta of 0.47, suggesting that its share price is 53% less volatile than the broader market.

Daxor has a net margin of 0.00% compared to Lifeward's net margin of -141.28%. Daxor's return on equity of 0.00% beat Lifeward's return on equity.

Daxor has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market. Comparatively, Lifeward has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market.

Lifeward has a consensus target price of $10.00, indicating a potential upside of 49.93%. Given Lifeward's higher probable upside, analysts plainly believe Lifeward is more favorable than Daxor.

Daxor has higher earnings, but lower revenue than Lifeward.

1.3% of Daxor shares are owned by institutional investors. Comparatively, 26.8% of Lifeward shares are owned by institutional investors. 51.5% of Daxor shares are owned by company insiders. Comparatively, 1.5% of Lifeward shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Lifeward had 1 more articles in the media than Daxor. MarketBeat recorded 2 mentions for Lifeward and 1 mentions for Daxor. Daxor's average media sentiment score of 0.00 equaled Lifeward'saverage media sentiment score.

Lifeward has lower revenue, but higher earnings than Outset Medical. Outset Medical is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Outset Medical has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market. Comparatively, Lifeward has a beta of 0.47, suggesting that its stock price is 53% less volatile than the broader market.

Outset Medical currently has a consensus price target of $10.00, indicating a potential upside of 143.90%. Lifeward has a consensus price target of $10.00, indicating a potential upside of 49.93%. Given Outset Medical's stronger consensus rating and higher possible upside, equities analysts plainly believe Outset Medical is more favorable than Lifeward.

In the previous week, Outset Medical had 1 more articles in the media than Lifeward. MarketBeat recorded 3 mentions for Outset Medical and 2 mentions for Lifeward. Outset Medical's average media sentiment score of 0.34 beat Lifeward's score of 0.00 indicating that Outset Medical is being referred to more favorably in the media.

Outset Medical has a net margin of -63.06% compared to Lifeward's net margin of -141.28%. Outset Medical's return on equity of -61.67% beat Lifeward's return on equity.

26.8% of Lifeward shares are held by institutional investors. 2.5% of Outset Medical shares are held by insiders. Comparatively, 1.5% of Lifeward shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lifeward has a net margin of -141.28% compared to Nano-X Imaging's net margin of -926.05%. Nano-X Imaging's return on equity of -116.93% beat Lifeward's return on equity.

26.8% of Lifeward shares are held by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are held by institutional investors. 1.5% of Lifeward shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lifeward has higher revenue and earnings than Nano-X Imaging. Lifeward is trading at a lower price-to-earnings ratio than Nano-X Imaging, indicating that it is currently the more affordable of the two stocks.

In the previous week, Lifeward and Lifeward both had 2 articles in the media. Lifeward's average media sentiment score of 0.00 equaled Nano-X Imaging'saverage media sentiment score.

Lifeward currently has a consensus target price of $10.00, suggesting a potential upside of 49.93%. Nano-X Imaging has a consensus target price of $4.33, suggesting a potential upside of 573.92%. Given Nano-X Imaging's stronger consensus rating and higher possible upside, analysts clearly believe Nano-X Imaging is more favorable than Lifeward.

Lifeward has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Nano-X Imaging has a beta of 1.28, meaning that its stock price is 28% more volatile than the broader market.